Last Updated: 25/11/2025
Primaquine radical cure of Plasmodium vivax malaria: a risk-benefit analysis
Objectives
This project aims to determine the risks and benefits of giving primaquine to cure vivax malaria using data from meta-analyses of published clinical trials and individual patient results from large multicentre trials.
Principal Institution
Principal Investigators / Focal Persons
Rationale and Abstract
Vivax malaria causes significant morbidity with over 100 million clinical cases each year and can cause a relapsing illness and chronic anaemia. The only available radical cure of P. vivax requires administration of primaquine, which can cause severe haemolysis in some patients.
External reference
Date
Jan 2016 — Dec 2019
Total Project Funding
$90,526
Funding Details
National Health and Medical Research Council (NHMRC) Australia, Australia
Grant ID: 1115347
AUD 122,714
Project Site
Related Resources
